These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30337526)

  • 41. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stimulus strength determines the BTK-dependence of the SHIP1-deficient phenotype in IgE/antigen-triggered mast cells.
    Zorn CN; Simonowski A; Huber M
    Sci Rep; 2018 Oct; 8(1):15467. PubMed ID: 30341350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
    Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
    Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane.
    Wang Q; Pechersky Y; Sagawa S; Pan AC; Shaw DE
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9390-9399. PubMed ID: 31019091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bruton's tyrosine kinase as a new therapeutic target.
    Uckun FM; Tibbles HE; Vassilev AO
    Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity.
    Middendorp S; Dingjan GM; Maas A; Dahlenborg K; Hendriks RW
    J Immunol; 2003 Dec; 171(11):5988-96. PubMed ID: 14634110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma.
    Riley MF; You MJ; Multani AS; Lozano G
    Oncogene; 2016 Jan; 35(3):358-65. PubMed ID: 25915849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
    Carr MI; Roderick JE; Zhang H; Woda BA; Kelliher MA; Jones SN
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15024-15029. PubMed ID: 27956626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.
    Khan WN
    Immunol Res; 2001; 23(2-3):147-56. PubMed ID: 11444380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
    Hopkins BT; Bame E; Bell N; Bohnert T; Bowden-Verhoek JK; Bui M; Cancilla MT; Conlon P; Cullen P; Erlanson DA; Fan J; Fuchs-Knotts T; Hansen S; Heumann S; Jenkins TJ; Marcotte D; McDowell B; Mertsching E; Negrou E; Otipoby KL; Poreci U; Romanowski MJ; Scott D; Silvian L; Yang W; Zhong M
    Bioorg Med Chem; 2019 Jul; 27(13):2905-2913. PubMed ID: 31138459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bruton's tyrosine kinase targets NF-kappaB to the bcl-x promoter via a mechanism involving phospholipase C-gamma2 following B cell antigen receptor engagement.
    Petro JB; Castro I; Lowe J; Khan WN
    FEBS Lett; 2002 Dec; 532(1-2):57-60. PubMed ID: 12459462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
    Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C
    Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
    Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
    Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Btk-dependent regulation of phosphoinositide synthesis.
    Carpenter CL
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):326-9. PubMed ID: 15046600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
    Zhai Z; Li R; Bai X; Ning X; Lin Z; Zhao X; Jin Y; Yin Y
    Bioorg Med Chem; 2019 Sep; 27(18):4124-4142. PubMed ID: 31395509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.
    Nyhoff LE; Clark ES; Barron BL; Bonami RH; Khan WN; Kendall PL
    J Immunol; 2018 Apr; 200(7):2352-2361. PubMed ID: 29483358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.